An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.
Every 36 weeks
Germany: Federal Institute for Drugs and Medical Devices